Malnutrition and cachexia in ovarian cancer patients: Pathophysiology and management

Anticancer Research

Volumn 21, Issue 4 B, 2001, Pages 2941-2947

  Gadducci, A ^a   Cosio, S ^a   Fanucchi, A ^a   Genazzani, A R ^a  

^a UNIVERSITY OF PISA   (Italy)

Author keywords

Bowel obstruction; Cachexia; Cytokine; Metabolism; Ovarian cancer

Indexed keywords

CYTOKINE; DOXIFLURIDINE; HALOPERIDOL; ICOSAPENTAENOIC ACID; INTERLEUKIN 6; MEGESTROL ACETATE; MELOXICAM; MORPHINE; OCTREOTIDE; PROSTAGLANDIN SYNTHASE INHIBITOR; SCOPOLAMINE BUTYL BROMIDE; TUMOR NECROSIS FACTOR;

CACHEXIA; CANCER PALLIATIVE THERAPY; CANCER SURGERY; ENERGY EXPENDITURE; FATTY ACID METABOLISM; GLUCONEOGENESIS; GLUCOSE METABOLISM; HUMAN; INTESTINE OBSTRUCTION; MALNUTRITION; NUTRITIONAL SUPPORT; OVARY CANCER; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW;

ADRENERGIC BETA-ANTAGONISTS; ANAEROBIOSIS; ANIMALS; ANOREXIA; ASCITES; CACHEXIA; CARBOHYDRATE METABOLISM; CHO CELLS; CRICETINAE; CRICETULUS; CYCLOOXYGENASE INHIBITORS; CYTOKINES; EICOSAPENTAENOIC ACID; ENERGY METABOLISM; FATTY ACIDS; FEMALE; FLOXURIDINE; GLYCOLYSIS; HUMANS; INTERLEUKIN-6; INTESTINAL OBSTRUCTION; INTUBATION, GASTROINTESTINAL; LINOLEIC ACID; LIPOLYSIS; LIPOPROTEIN LIPASE; MEGESTROL ACETATE; MICE; MICE, NUDE; NAUSEA; NUTRITION DISORDERS; OVARIAN NEOPLASMS; PALLIATIVE CARE; PARENTERAL NUTRITION, TOTAL; PROTEINS; QUALITY OF LIFE; TRANSFECTION; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0035160094     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (92)

1. Biology of cachexia
2. The role of cytokines in cancer cachexia
3. Cachexia, the metabolic component of neoplastic diseases
4. Pathophysiology of malnutrition in the adult cancer patient
5. Central nervous system mechanisms contributing to the cachexia-anorexia syndrome
6. Effects of administration of oral branched-chain amino acids on anorexia and caloric intake in cancer patients
7. A controlled trial of cyproheptadine in cancer patients with anorexia and/or cachexia
8. Resting energy expenditure in malnourished patients with and without cancer
9. A review of cancer cachexia and abnormal glucose metabolism in humans with cancer
10. Fatty acid and glycerol kinetics in septic patients and in patients with gastrointestinal cancer. The response to glucose infusion and parenteral feeding
11. Anorexia and weight loss in cancer patients
12. Beta-adrenoceptor activity and resting energy metabolism in weight losing cancer patients
13. Skeletal muscle metabolism in patients with malignant tumor
14. Ubiquitin gene expression is increased in skeletal muscle of tumour-bearing rats
15. Muscle protein waste in tumor-bearing rats is effectively antagonized by a beta 2-adrenergic agonist (clenbuterol). Role of the ATP ubiquitin-dependent proteolytic pathway
16. Cachectin and tumour necrosis factor as two sides of the same biological coin
17. Characterization of differentiation factor/leukaemia inhibitory factor effect on lipoprotein lipase activity and mRNA in 3T3-L1 adipocytes
18. Effects of tumour necrosis factor alpha (TNF alpha) on glucose transport and lipid metabolism of newly-differentiated human fat cells in cell culture
19. TNF can directly induce the expression of ubiquitin-dependent proteolytic system in rat soleus muscles
20. Pentoxifylline for treatment of cancer anorexia and cachexia? A randomized, double-blind, placebo controlled-trial
21. Evidence for the involvement of interleukin 6 in experimental cancer cachexia
22. Involvement of human interleukin 6 in experimental cachexia induced by a human uterine cervical carcinoma xenograft
23. Interleukin 6 receptor antibody inhibits muscle atrophy and, modulates proteolytic systems in interleukin 6 transgenic mice
24. Interleukin-6 induces proteolysis by activating intracellular proteases (cathepsins B and L, proteasome) in C2C12 myotubes
25. Regulation of food intake and hepatic protein synthesis by recombinant-derived cytokines
26. Interferons and tumor necrosis factors have similar catabolic effects on 3T3 L1 cells
27. Cancer cachexia syndrome developed in nude mice bearing melanoma cells producing leukemia-inhibitory factor
28. Increased expression of the mRNA for the hormone-sensitive lipase in adipose tissue of cancer patients
29. Hormone sensitive lipase
30. Production of lipolytic and proteolytic factors by a murine tumor-producing cachexia in the host
31. Alteration of serum and urinary lipolytic activity with weight loss in cachectic cancer patients
32. Lipolytic activity in adipose tissue of mice bearing Ehrlich ascites carcinoma
33. Identification of a human tumor-derived lipolysis-promoting factor
34. Catabolism of adipose tissue by a tumour-produced lipid-mobilising factor
35. Alterations in serum lipolytic activity of cancer patients with response to therapy
36. Purification and characterization of a tumor lipid-mobilizing factor
37. Biological evaluation of a lipid-mobilizing factor isolated from the urine of cancer patients
38. Mechanism of muscle protein degradation in cancer cachexia
39. Bioactivity of skeletal muscle proteolysis-inducing factors in the plasma proteins from cancer patients with weight loss
40. Induction of muscle protein degradation and weight'loss by a tumor product
41. Purification and characterization of a lipid-mobilizing factor associated with cachexia-inducing tumours in mice and humans
42. Characterization of a cancer cachectic factor
43. Induction of cachexia in mice by a product isolated from the urine of cachectic cancer patients
44. Ovarian cancer cachexia-surgical interactions
45. Surgical cytoreduction for advanced ovarian cancer
46. Nutrition and nutritional support in gynaecological cancer
47. Cachessia neoplastica
48. Tumors secreting human TNF/cachectin induce cachexia in mice
49. Evidence for tumor necrosis factor/cachectin production in cancer
50. Quantitation of tumor necrosis factor-α, interleukin-1B, and interleukin-6 in the effusions of ovarian epithelial neoplasms
51. Tumor necrosis factor and its receptors in human ovarian cancer. Potential role in disease progression
52. Serum levels of tumor necrosis factor (TNF), soluble receptors for TNF (55- and 75-kDa sTNFr), and soluble CD14 (sCD14) in epithelial ovarian cancer
53. Chinese hamster ovarian cells transfected with the murine interleukin-6 gene cause hypercalcemia as well as cachexia, leukocytosis and thrombocytosis in tumor-bearing nude mice
54. Serum interleukin-6 levels correlate with disease status in patients with epithelial ovarian cancer
55. Prognostic significance of interleukin 6 serum levels in patients with ovarian cancer
56. Aberrations in normal systemic lipid metabolism in ovarian cancer patients
57. Insulin and glucose status, tissue and plasma lipids in patients with tumours of the ovary or endometrium: Possible dietary implications
58. Effects of polyunsaturated fatty acids of the growth of murine colon adenocarcinomas in vitro and in vivo
59. Effect of patient-derived lipids on in vitro expression of oncogenes by ovarian tumor cells
60. The prognostic value of oncogenic antigen 519 (OA-519) expression and proliferative activity detected by antibody MIB-1 in nodenegative breast cancer
61. Increased expression of fatty acid synthase (OA-519) in ovarian neoplasms predicts shorter survival
62. Inhibition of fatty acid synthesis delays disease progression in xenograft model of ovarian cancer
63. Anemia-inducing substance (AIS) in advanced cancer: Inhibitory effect of AIS on the function of erythrocytes and immunocompetent cells
64. Anemia-inducing substance from plasma of patients with advanced malignant neoplasms
65. Removal of immunosuppressive substance in cancer patients' serum
66. Bowel obstruction in patients with ovarian carcinoma: Analysis of prognostic factors
67. Bowel obstruction in ovarian carcinoma: A retrospective study and review of the literature
68. Pseudo-obstruction of the large bowel
69. Management of bowel obstruction in advanced cancer
70. Intestinal obstruction in patients with advanced malignant disease
71. Surgical management of bowel obstruction in advanced ovarian carcinoma
72. Bowel obstruction in patients with ovarian cancer: A search for prognostic factors
73. Parenteral nutrition in cancer patients undergoing chemotherapy: A meta-analysis
74. Bodycomposition changes in patients who gain weight while receiving megestrol acetate
75. Improved quality of life with megestrol acetate in patients with endocrine-insensitive advanced cancer: A randomised placebo-controlled trial
76. Megestrol acetate in advanced, progressive, hormone-insensitive cancer. Effects of the quality of life: A placebo-controlled, randomised, multicentre trial
77. Randomized comparison of megestrol acetate versus dexamethasone versus floxymestrone for the treatment of cancer anorexia/cachexia
78. Ibuprofen reduces energy expenditure and acute-phase protein production compared with placebo in pancreatic cancer patients
79. Effect of cyclooxygenase and nitric oxide synthase inhibitors on tumor growth in mouse tumor models with and without cancer cache- xia related to prostanoids
80. The effect of polyunsatured fatty acids on the progress of cachexia in patients with pancreatic cancer
81. Inhibition of tumour-induced lipolysis in vitro and cachexia and tumour growth in vivo by eicosapentaenoic acid
82. Anticachectic and antitumor effect of eicosapentaenoic acid and its effect on protein turnover
83. Effect of a fluorinated pyrimidine on cachexia and tumour growth in murine cachexia models: Relationship with a proteolysis inducing factor
84. Effect of the specific cyclooxygenase- 2 inhibitor meloxicam on tumor growth and cachexia in a murine model
85. Elimination of anemia-inducing substance by cyclic plasma perfusion of tumor-bearing rabbits
86. Surgical management of intestinal obstruction in ovarian cancer. I. Clinical features, postoperative complications, and survival
87. Management of bowel obstruction in advanced and terminal cancer patients
88. Survival after intestinal obstruction in patients with fatal ovarian cancer: Analysis of prognostic variables
89. Octreotide in the management of gastrointestinal obstruction in terminal cancer patients
90. Octreotide in the management of bowel obstruction in terminal ovarian cancer
91. Palliation of small bowel obstruction by percutaneous gastrostomy in patients with progressive ovarian carcinoma
92. Percutaneous endoscopic gastrostomy (PEG) in palliative treatment of non-operable intestinal obstruction due to gynecologic cancer: A review